Wednesday, July 8, 2026

biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF

Aptose Biosciences

Aptose Biosciences clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Diego, USA HQ
2014 Founded
32 Employees
Public company Type
APTOF · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2014
Employees
32
Programs
8
Drugs
1
Patents
7
Intelligence · Clinical Programs

Aptose Biosciences projects

4 ClinicalTrials.gov programs sponsored by Aptose Biosciences.

Aptose Biosciences has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. APTO-253

    Aptose Biosciences

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial
  2. CG-806

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial
  3. CG-806

    Aptose Biosciences

    Chronic Lymphocytic Leukemia

    phase 1 small molecule terminated

    1 trial
  4. LOR-253 HCl

    Aptose Biosciences

    Advanced or Metastatic Solid Tumours

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Aptose Biosciences have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.